GOTHENBURG, Sweden, December 5, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced on December 3 that the ongoing phase III study AGENT will not reach 300 PFS events with current censoring rules based on FDA decision. Following this announcement, Isofol invites investors, analysts, and media to an audiocast (in English) with a Q&A-session on December 6, at 08:00 a.m. CET.
The presentation will be held by Isofol’s CEO Ulf Jungnelius and CMO Roger Tell in English and will conclude with a Q&A session. Questions can be asked on the telephone conference or in written form through the webcast. No preregistration is needed.
Date and time
December 6, 2021, at 08:00 a.m. CET
Call in details will be made available at the following link in good time before the start of the presentation:
The presentation will also be available on Isofol’s website after the broadcast.
For further information, please contact
Isofol Medical AB (publ)
Ulf Jungnelius, M.D., Chief Executive Officer
Phone: +46 (0) 709 16 89 55
The information was submitted for publication, through the agency of the contact person set out above, at 12:00 CET on December 5, 2021.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is traded on the Nasdaq Stockholm.